Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Response to letter to the editor by Mondal H et al. “Delayed breakfast in type 2 diabetes: Critical gaps and translation barriers”","authors":"Ana Paula Bravo-Garcia, Evelyn B. Parr","doi":"10.1016/j.dsx.2025.103332","DOIUrl":"10.1016/j.dsx.2025.103332","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 11","pages":"Article 103332"},"PeriodicalIF":3.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) , Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2025.103354","DOIUrl":"10.1016/j.dsx.2025.103354","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 11","pages":"Article 103354"},"PeriodicalIF":3.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and risk factors of hypovitaminosis D among patients with diabetes mellitus from India: A systematic review and meta-analysis","authors":"Gaurab Bhaduri ,&nbsp;Shambo Samrat Samajdar ,&nbsp;Subhro Chakraborty ,&nbsp;Banshi Saboo ,&nbsp;Shashank R. Joshi","doi":"10.1016/j.dsx.2025.103326","DOIUrl":"10.1016/j.dsx.2025.103326","url":null,"abstract":"<div><h3>Background</h3><div>There is considerable evidence regarding the potential risk of hypovitaminosis D for various chronic conditions, including type 2 diabetes mellitus (T2DM). Although India essentially shares a tropical climate, it reports a high prevalence of vitamin D deficiency that is predominant in people with diabetes. This systematic review and meta-analysis were designed to look into the risk factors associated with hypovitaminosis D in diabetic patients from India and assess the prevalence.</div></div><div><h3>Methods</h3><div>PubMed, Embase, and Cochrane Library were searched systematically for observational studies reporting the serum vitamin D levels of T2DM patients up to September 2024. A random effects model was employed to analyse the pooled prevalence of hypovitaminosis D and its risk factors.</div></div><div><h3>Results</h3><div>Twelve studies of 8953 patients with diabetes (sample size) were included in the review. The combined prevalence of hypovitaminosis D was 79 % (95 % CI: 75 %–84 %, i² = 97 %). Mean serum vitamin D level was 17.21 ng/mL (95 % CI: 16.87–17.56 ng/mL). More frequently noted risk factors included duration of diabetes, fatigue, body mass index, and HbA1c levels. However, the findings are limited by substantial heterogeneity, predominance of cross-sectional designs, and a paucity of high-quality, well-controlled studies from India.</div></div><div><h3>Conclusion</h3><div>Hypovitaminosis D is highly prevalent in Type 2 diabetes mellitus patients in India, with the level highly below optimum thresholds. Routine screening of vitamin D levels and targeted supplementation strategies may further improve metabolic control and reduce complications among this vulnerable population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103326"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor: Malnutrition-related diabetes mellitus: Rushing toward “type 5” amid unresolved questions and limited evidence","authors":"Alok Bhatt ,&nbsp;Pentela Bhavani ,&nbsp;Ashwini Kumar Sapate ,&nbsp;Fayaz Ahamed","doi":"10.1016/j.dsx.2025.103315","DOIUrl":"10.1016/j.dsx.2025.103315","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103315"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145448494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term 24h dietary recalls from observational studies cannot support claims on mortality","authors":"Emily N.C. Manoogian ,&nbsp;Courtney M. Peterson ,&nbsp;Dorothy D. Sears ,&nbsp;Mary Playdon ,&nbsp;Siobhan Banks ,&nbsp;Maxine Bonham ,&nbsp;Amandine Chaix ,&nbsp;Lisa S. Chow ,&nbsp;Adriana Coletta ,&nbsp;Rafael De Cabo ,&nbsp;Paula Desplats ,&nbsp;Charna Dibner ,&nbsp;Kelsey Gabel ,&nbsp;Sheri L. Johnson ,&nbsp;Lance J. Kriegsfeld ,&nbsp;Sheetal Hardikar ,&nbsp;John A. Hawley ,&nbsp;Leonie K. Heilbronn ,&nbsp;John Hogenesch ,&nbsp;Dara L. James ,&nbsp;Tinh-Hai Collet","doi":"10.1016/j.dsx.2025.103316","DOIUrl":"10.1016/j.dsx.2025.103316","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103316"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145498160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2025.103344","DOIUrl":"10.1016/j.dsx.2025.103344","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103344"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential associations between smoking, e-cigarette use, and diabetes prevalence","authors":"Yusuff Adebayo Adebisi ,&nbsp;Chimwemwe Ngoma ,&nbsp;Davide Campagna ,&nbsp;Antonio Ceriello ,&nbsp;Najim Z. Alshahrani ,&nbsp;Anoop Misra ,&nbsp;Abdul Basit ,&nbsp;Cristina Russo ,&nbsp;Tadej Battelino ,&nbsp;Noel Somasundaram ,&nbsp;Muhammad Yazid Jalaludin ,&nbsp;Phuong Le Dinh ,&nbsp;Yoshifumi Saisho ,&nbsp;Magdalena Walicka ,&nbsp;Venera Tomaselli ,&nbsp;Giulio Cantone ,&nbsp;Othmar Moser ,&nbsp;Riccardo Polosa","doi":"10.1016/j.dsx.2025.103331","DOIUrl":"10.1016/j.dsx.2025.103331","url":null,"abstract":"<div><h3>Background</h3><div>Cigarette smoking is a well-established risk factor for diabetes, but the relationship between e-cigarette use and diabetes remains uncertain. Evidence to date has been drawn almost entirely from North America and Asia, with little information from European populations.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study of 17,854 adults aged 16 years and older from the 2017, 2018, 2019, and 2021 waves of the nationally representative Scottish Health Survey. Diabetes status was based on self-report of doctor-diagnosed diabetes. Participants were classified into six mutually exclusive categories of smoking and e-cigarette use: never users of either cigarettes or e-cigarettes, ex-smokers (former smokers who never used e-cigarettes), current exclusive cigarette smokers, current exclusive e-cigarette users, current dual users, and former e-cigarette users. Weighted prevalence estimates and survey-weighted binary logistic regression models were used to examine associations, adjusting for age group, sex, education, deprivation quintile, ethnicity, alcohol use, physical activity, and hypertension.</div></div><div><h3>Results</h3><div>Diabetes prevalence was highest among ex-smokers (11.3 %, 95 % CI: 10.1–12.5). Prevalence was 5.7 % (95 % CI: 5.2–6.2) among never users of either cigarettes or e-cigarettes, 6.2 % (95 % CI: 4.9–7.9) among current exclusive cigarette smokers, 4.9 % (95 % CI: 3.4–7.1) among current exclusive e-cigarette users, 8.3 % (95 % CI: 5.8–11.8) among current dual users, and 5.1 % (95 % CI: 4.1–6.3) among former e-cigarette users. In adjusted models, ex-smokers had 35 % higher odds of diabetes compared with never users of either cigarettes or e-cigarettes (OR = 1.35, 95 % CI = 1.14–1.60, p &lt; 0.001), whereas current exclusive smokers (OR = 0.78, 95 % CI = 0.58–1.03, p = 0.084), current exclusive e-cigarette users (OR = 0.81, 95 % CI = 0.53–1.22, p = 0.309), current dual users (OR = 1.49, 95 % CI = 0.94–2.38, p = 0.091), and former e-cigarette users (OR = 1.00, 95 % CI = 0.78–1.29, p = 0.973) were not significantly different from never users. Sensitivity analyses restricting ex-smokers to those with ≥5 years since cessation and limiting the sample to adults aged ≥45 years reproduced the same pattern of results.</div></div><div><h3>Conclusions</h3><div>In this nationally representative study of Scottish adults, excess diabetes prevalence was observed among ex-smokers, a pattern that may reflect both reverse causation if individuals quit smoking after diagnosis and the lasting metabolic effects of cumulative smoking exposure. Neither current nor former e-cigarette use was associated with diabetes, and the observed variation in prevalence appeared linked to smoking history rather than e-cigarette use. However, because vaping is relatively recent, further longitudinal research is needed to clarify any long-term risks.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103331"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artichoke and cardiometabolic health: A systematic and meta-analytic synthesis of current evidence","authors":"Ali Jafari ,&nbsp;Mohammad Amin Karimi ,&nbsp;Mahsa Mahmoudinezhad ,&nbsp;Fatemeh Razavi ,&nbsp;Helia Mardani ,&nbsp;Vali Musazadeh","doi":"10.1016/j.dsx.2025.103328","DOIUrl":"10.1016/j.dsx.2025.103328","url":null,"abstract":"<div><h3>Background and aims</h3><div>This systematic review and meta-analysis was conducted to evaluate the effects of artichoke supplementation on cardiometabolic health markers in adults.</div></div><div><h3>Methods</h3><div>A comprehensive literature search of PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to September 2024.</div></div><div><h3>Results</h3><div>Artichoke supplementation significantly reduced body mass index (WMD = −0.51 kg/m², 95 % CI: 0.93 to −0.09) and waist circumference (WMD = −1.21 cm, 95 % CI: 2.24 to −0.17), while its effects on body weight and hip circumference were not statistically significant. Blood pressure outcomes revealed significant reductions in both systolic (WMD = −2.49 mmHg, 95 % CI: 4.33 to −0.65) and diastolic (WMD = −1.53 mmHg, 95 % CI: 3.01 to −0.05) pressures. Significant lipid profile improvements were observed in total cholesterol (WMD = −12.29 mg/dL, 95 % CI: 19.92 to −4.65), low-density lipoprotein cholesterol (WMD = −10.31 mg/dL, 95 % CI: 18.57 to −2.04), and triglycerides (WMD = −12.85 mg/dL, 95 % CI: 24.77 to −0.93), with no significant effect on high-density lipoprotein cholesterol. Regarding glycemic indices, insulin (WMD = −1.83 mU/L, 95 % CI: 3.33 to −0.32) and homeostatic model assessment for insulin resistance (WMD = −0.92, 95 % CI: 1.33 to −0.51) were significantly reduced, whereas fasting blood glucose and HbA1c were unaffected. Among liver function markers, alanine aminotransferase (WMD = −8.47 U/L, 95 % CI: 14.71 to −2.23) and alkaline phosphatase (WMD = −7.86 U/L, 95 % CI: 15.26 to −0.45) were significantly reduced, while aspartate aminotransferase showed a borderline non-significant effect. No significant change was observed in creatinine levels.</div></div><div><h3>Conclusion</h3><div>Artichoke supplementation may offer modest but significant improvements in several cardiometabolic risk markers.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103328"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From 1990 to 2021, the burden of diabetes among the elderly in the Western Pacific Region (WPR) and projections for 2040 prevalence: A systematic analysis of the 2021 Global Burden of Disease study","authors":"Yve Han ,&nbsp;Huaxing Lou ,&nbsp;Peng Zhao ,&nbsp;Hui Li ,&nbsp;Congyi Zhang ,&nbsp;Hongru Sun","doi":"10.1016/j.dsx.2025.103324","DOIUrl":"10.1016/j.dsx.2025.103324","url":null,"abstract":"<div><h3>Aims</h3><div>The study aims to quantify the changes in the age-standardized prevalence of Type 1 and type 2 diabetes among the elderly in the Western Pacific Region (WPR) from 1990 to 2021.</div></div><div><h3>Methods</h3><div>We analyzed data on diabetes prevalence, mortality, and DALYs among the elderly from the GBD, stratified by sex, age, and SDI. We calculated ASR, used APC and AAPC to assess trends, and conducted correlation, decomposition, and health inequality analyses.</div></div><div><h3>Results</h3><div>From 1990 to 2021, the age-standardized prevalence of type 1 and type 2 diabetes increased in the region's elderly. In 2021, rates were 19,573.81 per 100,000 for type 2 and 191.98 per 100,000 for type 1. Men experienced a higher burden, and type 2's burden increased with age. A negative SDI-diabetes burden correlation was observed, highlighting socio-economic complexities.</div></div><div><h3>Conclusion</h3><div>The rising trends in diabetes prevalence and DALYs among the elderly in the Western Pacific Region underscore the growing challenge of managing diabetes in an aging society. This highlights the need for targeted interventions and policies to address the health impacts of diabetes on the elderly population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103324"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities","authors":"Melanie J. Davies ,&nbsp;Amra Ciric Alibegovic ,&nbsp;Anders Boeck Jensen ,&nbsp;Renuka Munikrishnappa ,&nbsp;Uffe Christian Braae","doi":"10.1016/j.dsx.2025.103327","DOIUrl":"10.1016/j.dsx.2025.103327","url":null,"abstract":"<div><h3>Aims</h3><div>This real-world study assessed glycemic levels and further clinical outcomes, following initiation of detemir, in sub populations of people with T2D vulnerable to hypoglycemia.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included people registered in the United Kingdom Clinical Practice Research Datalink (CPRD) GOLD database who initiated detemir between January 2004 and December 2019. Analyses were stratified by age, previous insulin experience, and history of renal, liver or cardiovascular disease (CVD).</div></div><div><h3>Results</h3><div>In total, 8975 eligible study participants were identified (44.4 %, aged ≥65 years; 23.7 %, renal disease; 15.6 %, CVD; 2.2 %, liver disease; 53.3 %, insulin-naïve). Six months post-index estimated changes (95 % confidence intervals [CI]) in HbA1c and body weight were −1.00 % (−1.1; −0.9) (−11 mmol/mol [−12; −9]) and 0.35 kg (0.03; 0.66), respectively. Rates of hypoglycemia were low, with no increase between pre- and post-index periods. Compared with pre-index, the mean number of oral glucose-lowering therapy prescriptions per person and mean number of people receiving each type of glucose-lowering therapy decreased post-index.</div></div><div><h3>Conclusions</h3><div>Detemir appears to be an effective and well-tolerated treatment for T2D in older people, and those with CVD, renal disease or liver disease.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103327"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}